|Title||Ferring Pharmaceuticals acquires generic ganirelix acetate injection rights|
|Description||Ferring Pharmaceuticals acquires generic ganirelix acetate injection rights Ferring Pharmaceuticals has a new addition to its generics portfolio. The Saint-Prex, Switzerland-based company, whose U.S. operations are headquartered in Parsippany, N.J., has acquired the U.S. commercialization rights for a generic version of ganirelix acetate injection from Sun Pharmaceutical Industries.Ganirelix Acetate powder Ganirelix is a GnRH antagonist used to prevent premature luteinizing hormone surges in women undergoing fertility treatment. “When beginning a treatment process as individualized and complex as fertility, it is critical that patients and providers have a wide variety of treatment options available,” said Gaurang Daftary, Ferring's reproductive medicine and women’s health senior medical director and adjunct professor in reproductive endocrinology at the Mayo Clinic and the Yale University School of Medicine. Sun Pharmaceutical has received the Food and Drug Administration’s blessing for a generic version of Organon’s Ganirelix acetate injection 250 mcg/0.5 mL. Ganirelix is an injectable competitive gonadotropin-releasing hormone antagonist, or GnRH antagonist. The medication is primarily used in assisted reproduction to control ovulation. The product had a market value of approximately $67 million for the 12 months ended September 2018, according to IQVIA.|
Please register or log in.